State of Alaska Department of Revenue Has $1.32 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

State of Alaska Department of Revenue reduced its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,890 shares of the biotechnology company’s stock after selling 145 shares during the quarter. State of Alaska Department of Revenue’s holdings in Sarepta Therapeutics were worth $1,324,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Truist Financial Corp grew its holdings in shares of Sarepta Therapeutics by 86.5% in the 2nd quarter. Truist Financial Corp now owns 4,003 shares of the biotechnology company’s stock valued at $632,000 after buying an additional 1,857 shares during the period. Blue Trust Inc. grew its holdings in Sarepta Therapeutics by 896.5% during the third quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 511 shares during the period. Bank Pictet & Cie Europe AG raised its stake in Sarepta Therapeutics by 27.7% in the third quarter. Bank Pictet & Cie Europe AG now owns 2,827 shares of the biotechnology company’s stock valued at $353,000 after buying an additional 613 shares during the period. International Assets Investment Management LLC boosted its holdings in shares of Sarepta Therapeutics by 59,222.7% during the third quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock worth $9,483,000 after acquiring an additional 75,805 shares during the period. Finally, Values First Advisors Inc. acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $59,000. Institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on SRPT. Evercore ISI reduced their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a report on Monday, January 27th. Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Jefferies Financial Group began coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average target price of $176.77.

Insider Activity at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $109.81 on Thursday. The business has a fifty day simple moving average of $120.16 and a two-hundred day simple moving average of $125.22. The firm has a market capitalization of $10.49 billion, a P/E ratio of 87.85 and a beta of 0.75. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12 month low of $102.15 and a 12 month high of $173.25.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.